Bioxytran Stock Price, News & Analysis

Bioxytran, Inc. (BIXT) is a clinical-stage biotechnology company that focuses on research and development in biotechnology, with an emphasis on therapies targeting viral infections, stroke, Alzheimer’s disease, hypoxia, and mitochondrial dysfunction. The company’s work spans antiviral drug development and oxygen transport technologies, reflecting a strategy built around galectin biology, oxygen therapeutics, and tissue-level metabolic monitoring.

According to recent disclosures and press releases, Bioxytran describes itself as a clinical-stage biotech company developing novel therapies for viral diseases, as well as drugs to treat stroke, Alzheimer’s disease, and other conditions linked to oxygen deprivation and mitochondrial impairment. The company trades on the OTCQB market under the ticker symbol BIXT and operates in the professional, scientific, and technical services sector under the category of research and development in biotechnology.

Antiviral Drug Platform and ProLectin-M

Bioxytran highlights a core focus on broad-spectrum antiviral therapies. Its leading antiviral drug candidate, ProLectin-M, is described as a complex carbohydrate therapeutic and galectin antagonist that targets viral entry mechanisms. Company news states that ProLectin-M is being developed as an oral antiviral based on sugar chemistry, under an active Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Press releases report that ProLectin-M has been evaluated in multiple randomized, double-blind, placebo-controlled clinical trials. Earlier studies cited by the company showed rapid viral clearance in mild-to-moderate COVID-19 patients, with high responder rates by day 3 and complete negative PCR tests by day 7, with no serious adverse events or viral rebounds in the observation period. A dose optimization trial has also been completed, assessing multiple doses versus placebo over several days with endpoints that include undetectable viral load by day 7, early viral clearance, symptom improvement, and safety and tolerability.

Bioxytran positions ProLectin-M as a broad-spectrum antiviral platform that targets the galectin fold on viral spike proteins. Company communications state that peer-reviewed studies and in vitro research have demonstrated the potential to neutralize viruses such as SARS-CoV-2, influenza, respiratory syncytial virus (RSV), and viruses similar to Bird Flu (H5N1), as well as Epstein-Barr Virus (EBV) in ongoing research. The company also notes that ProLectin-M is being explored as a first-line therapy candidate for upper respiratory viral infections and pandemic preparedness.

Galectin Antagonists and PHM23

Beyond ProLectin-M, Bioxytran reports development of additional galectin antagonist molecules, including PHM23. Company news describes PHM23 as an antiviral candidate that blocks viral spike proteins from attaching to host cells by targeting galectins, proteins implicated in viral replication, inflammation, and fibrosis. In vitro studies referenced by the company indicate activity against viruses similar to Bird Flu.

PHM23 has been selected by the University of Georgia for inclusion in a grant submission to the U.S. Department of Agriculture’s Highly Pathogenic Avian Influenza (HPAI) Poultry Innovation Grand Challenge. Bioxytran highlights this selection as recognition of PHM23’s potential role in addressing Bird Flu (H5N1) and other viral threats in poultry, and as an example of how its galectin antagonist platform may extend into animal health and agricultural applications.

Oxygen Transport, BXT-25, and Universal Oxygen Carrier (UOC)

A second major pillar of Bioxytran’s work is oxygen therapeutics. The company reports that it is developing BXT-25, described as a universal oxygen carrier designed to permeate blood clots and deliver oxygen to tissues affected by ischemia and hypoxia. Bioxytran states that BXT-25 is being advanced toward Phase 1 clinical trials for conditions where an oxygen transport carrier is needed, including ischemic stroke, heart attack, pulmonary embolism, chronic kidney disease, Long Covid, and other hypoxic diseases.

Bioxytran also refers to a broader Universal Oxygen Carrier (UOC) project, which is closely tied to BXT-25. The company has entered into a joint venture with the Heme Foundation to develop a UOC and has secured a source of GMP-quality camel hemoglobin for this purpose. Company communications describe camel hemoglobin as having properties that make it attractive for oxygen transport, such as resilience in harsh conditions and stability that may support its use as a building block for oxygen carriers. Under the joint venture, Bioxytran retains intellectual property rights related to UOC development, and the company notes that advances in this project may support further work on BXT-25.

Stroke, Alzheimer’s, and Oxygenation Diagnostics

Bioxytran’s disclosures emphasize a focus on stroke, Alzheimer’s disease, and other neurodegenerative or hypoxic conditions. The company states that BXT-25 is intended to address one of the key challenges in stroke treatment: the narrow time window for effective intervention. It describes BXT-25 as an ambulatory treatment concept that could potentially reduce time to treatment by delivering oxygen through blood clots, with the goal of improving outcomes in stroke and related conditions.

The company also highlights its alignment with research on tissue oxygenation and mitochondrial function. Bioxytran references scientific work by advisors such as Prof. Avraham Mayevsky, including publications on body oxygen homeostasis, mitochondrial function, and the Mongolian gerbil brain model for ischemic stroke and neurodegenerative diseases. These works are presented as scientific foundations for Bioxytran’s clinical development of UOC and BXT-25.

In its communications, Bioxytran notes the use of the MDX Viewer, an FDA-approved device that measures tissue oxygenation and metabolic status in real time. The company describes plans to integrate this type of precision diagnostic into BXT-25 clinical trials as a biomarker to monitor oxygen consumption in the brain during stroke and to assess tissue response to UOC-based therapies. Bioxytran characterizes this shift from peripheral oxygen measurements to tissue-specific monitoring as central to its approach to stroke, Alzheimer’s disease, and other hypoxic or mitochondrial disorders.

Scientific and Clinical Orientation

Bioxytran presents itself as building on decades of research in mitochondrial function, NADH redox state monitoring, and oxygen regulation. Company releases reference historical milestones in fiber optic–based fluorometry and in vivo NADH monitoring, linking these scientific advances to the rationale behind BXT-25 and UOC development. The firm emphasizes the role of mitochondrial dysfunction and hypoxia as contributors to diseases such as stroke and neurodegeneration, and positions its drug candidates as attempts to address these underlying mechanisms.

On the antiviral side, Bioxytran describes its approach as rooted in glycovirology, using proprietary linear complex carbohydrate structures to block galectins and conserved regions of viral spike proteins. This platform is presented as a way to potentially neutralize a range of respiratory and other viruses, with clinical and preclinical data cited in company communications to support continued development.

Corporate Governance and Oversight

Recent SEC Form 8-K filings provide insight into aspects of Bioxytran’s corporate governance. One filing reports the resignation of a member of the Board of Directors and Chair of the Audit Committee, who recommended enhancements to the company’s oversight framework, internal controls, and approval processes. In response, Bioxytran states that it engaged an independent third-party financial expert to review its oversight, internal control, and approval procedures and to provide recommendations to the Board.

Another Form 8-K discloses the termination of an officer of the company, with a note that the former officer is contesting the reason for dismissal in relation to potential severance benefits. These filings illustrate that Bioxytran is making formal SEC disclosures regarding changes in officers and directors and is addressing governance and control matters through external review.

Company Status and Market Context

Available information describes Bioxytran as a micro-cap, clinical-stage biotechnology company whose stock trades on the OTCQB market. The company’s communications emphasize that it is pursuing development of platform technologies in virology, oxygen transport, and cancer metastasis, and that it is seeking strategic partnerships, collaborations, and potential licensing arrangements to support further development and commercialization of its drug candidates.

Bioxytran’s public statements also mention high insider ownership and a reliance on strategic funding and partnerships to advance clinical programs. However, detailed financial metrics, market capitalization figures, and specific revenue streams are not provided in the materials summarized here.

Key Focus Areas

• Broad-spectrum antivirals: Development of ProLectin-M and PHM23 as galectin antagonist therapies targeting viral entry and replication.
• Oxygen therapeutics: Development of BXT-25 and a Universal Oxygen Carrier to address hypoxia in stroke, Alzheimer’s disease, heart attack, pulmonary embolism, chronic kidney disease, and related conditions.
• Tissue oxygenation diagnostics: Integration of devices such as the MDX Viewer to measure tissue oxygenation and metabolic status in real time for clinical trial assessment.
• Scientific foundations: Alignment with published research on mitochondrial function, NADH redox state, and animal models of ischemic stroke and neurodegenerative disease.
• Corporate governance: SEC-reported changes in board composition and officers, along with engagement of an independent expert to review internal controls and approval processes.

Overall, Bioxytran, Inc. presents itself as a biotechnology company focused on translating research in galectins, oxygen transport, and mitochondrial function into drug candidates and clinical programs aimed at viral infections, stroke, Alzheimer’s disease, and other hypoxia-related conditions.